Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UAE (United Arab Emirates) fears breast cancer increase:

This article was originally published in Clinica

Executive Summary

The number of breast cancer cases in the UAE is rising. In spite of a government initiative to increase awareness earlier this year, women have little understanding of the disease, meaning that they do not opt to for screening. Sana'a Awad obstetrician and gynaecologist at Al Mousa Medical Centre in Dubai said: "When women reach 40, they should undergo an X-ray once every year. But if there is a breast cancer case in their family history, then they should have mammogram X-rays twice a year, after the age of 35." According to Fatima Mohammed Khamis, head of the maternity and child care unit at Khor Fakkan Hospital, 30% of women aged 30-39 suffer from breast cancer in the UAE, with 37% of women aged 40-49 and around 29% of women above 50 suffering from the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT068745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel